AACR Special Conference in Cancer Research: Bladder Cancer: Transforming the Field
May 17-20, 2024
Le Méridien Charlotte
Charlotte, North Carolina
CONFERENCE COHAIRS
Lars Dyrskjøt Aarhus University, Aarhus, Denmark
Donna E. Hansel, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dan Theodorescu, Samuel Oschin Comprehensive Cancer Institutue at Cedars-Sinai Medical Center, Los Angeles, California
Tahlita C. M. Zuiverloon, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
Bladder cancer (BC) ranks as the tenth most prevalent malignant ailment worldwide, with an annual occurrence of roughly 573,000 novel cases and 212,536 fatalities. Irrespective of geographical, racial, and socioeconomic divisions, men exhibit a higher susceptibility to bladder cancer compared to women, and the likelihood of developing the disease rises with advancing age. Bladder cancer initiates from the transitional epithelium, with urothelial BC constituting the predominant subtype, responsible for over 90% of instances. While the clinical management of bladder cancer has experienced minimal advancements in the past three decades, this trajectory has substantially shifted in recent years. Progress in comprehending the biology of bladder cancer, accompanied by extensive gene expression and sequencing initiatives, has led to more targeted therapeutic interventions and efficacious immunotherapies.
The comprehensively structured conference program will interweave sessions addressing core biological principles, disease models, and the clinical aspects of bladder cancer. Encompassing groundbreaking breakthroughs and their potential implications, the conference will span the entire spectrum of bladder cancer, from foundational biology to practical clinical applications. Moreover, the conference seeks to convene globally recognized pioneers in the field of bladder cancer, emphasizing diversity in terms of geography, ethnicity, and gender. It also aims to facilitate interactions and collaborations among scientists and physicians across relevant disciplines, fostering a collaborative environment for advancing knowledge and innovation.
PROFESSIONAL EDUCATIONAL GRANTS
Bristol Myers Squibb
Pfizer
Continuing Medical Education Activity AMA PRA Category 1 CreditsTM available
